Suven Pharmaceuticals saw a strong rally in its stock price, jumping over 3% after global brokerage Macquarie initiated an Outperform rating. The firm has set a target price of ₹1,500, citing Suven’s strong position in high-growth CDMO segments.
Macquarie sees Suven Pharma as a key player in the evolving Contract Development and Manufacturing Organization (CDMO) market. The brokerage highlights two major growth drivers for the company:
- Antibody-Drug Conjugates (ADC) Platform – Suven has built a solid presence in this cutting-edge space, which is gaining rapid traction in the pharma outsourcing industry.
- Oligonucleotide Manufacturing Expansion – This emerging area is expected to fuel future revenue growth and enhance profitability.
Suven Pharma’s proven track record in traditional CDMO businesses, along with its focus on innovative therapies, makes it a strong bet for long-term investors.
Suven Pharma shares opened at ₹1,097.05, reaching a high of ₹1,134.60 and a low of ₹1,087.70. The stock remains strong, with a 52-week high of ₹1,360.00 and a low of ₹598.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
